Article Text
PDFTherapeutics
Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia
Statistics from Altmetric.com
Footnotes
Sources of funding: The Veterans Affairs Cooperative Studies Program. An unrestricted grant and the study drug (long acting risperidone) were provided by Ortho-McNeil Janssen Scientific Affairs, LLC.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions